These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34203328)

  • 21. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
    Singh M; Ganguly NK; Kumar L; Vohra H
    Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
    Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever.
    Das S; Chowdhury R; Pal A; Okamoto K; Das S
    Immunobiology; 2019 May; 224(3):371-382. PubMed ID: 30952553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.
    Townsend K; Ladhani SN; Findlow H; Borrow R
    Vaccine; 2014 Sep; 32(43):5650-6. PubMed ID: 25138290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children.
    Chinnasami B; Sadasivam K; Vivekanandhan A; Arunachalam P; Pasupathy S
    J Clin Diagn Res; 2015 May; 9(5):SC01-3. PubMed ID: 26155525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
    Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
    J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis.
    Khanam F; Kim DR; Liu X; Voysey M; Pitzer VE; Zaman K; Pollard AJ; Qadri F; Clemens JD
    EClinicalMedicine; 2023 Apr; 58():101925. PubMed ID: 37090439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing invasive salmonellosis in children through vaccination.
    Principi N; Esposito S
    Expert Rev Vaccines; 2016 Jul; 15(7):897-905. PubMed ID: 27140662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Vi conjugate - a new generation of typhoid vaccine.
    Szu SC
    Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.
    Keddy KH; Klugman KP; Hansford CF; Blondeau C; Bouveret le Cam NN
    Vaccine; 1999 Jan; 17(2):110-3. PubMed ID: 9987143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.
    Roggelin L; Vinnemeier CD; Fischer-Herr J; Johnson-Weaver BT; Rolling T; Burchard GD; Staats HF; Cramer JP
    Vaccine; 2015 Aug; 33(33):4141-5. PubMed ID: 26144902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of two Salmonella typhimurium hybrids as challenge organisms in a system for the assay of typhoid vaccines.
    Johnson EM; Diena BB; Lior H; Ryan A; Krol P; Baron LS
    Infect Immun; 1982 Oct; 38(1):201-5. PubMed ID: 6754614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.